Kala Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

KALA BIO

11/08/2022 14:33

* Kala Pharmaceuticals Inc  KALA.OQ  reported a quarterly
adjusted
loss of 38 cents​​ per share for the quarter ended in June. The
mean expectation of four analysts for the quarter was for a loss
of 43 cents per share.
    * Revenue fell 31.2% to $2.10 million from a year ago;
analysts
expected $2.02 million. 
    * Kala Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 38 cents​.
    * The mean earnings estimate of analysts had fallen by
about 26.1%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Kala Pharmaceuticals Inc shares had risen by 16.0% this
quarter and lost 71.2% so far this year.
    * The company reported a quarterly loss of $25.7 million.
    * Wall Street's median 12-month price target for Kala
Pharmaceuticals Inc is $2.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 11
at 01:33 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.43          -0.38          Beat
 Mar. 31 2022      -0.36          -0.45          Missed
 Dec. 31 2021      -0.41          -0.68          Missed
 Sep. 30 2021      -0.43          -0.43          Met